MedTrace Logo

Surgery Plus Medroxyprogesterone in Preventing Endometrial Cancer

NCT00003179 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 360

Last updated 2013-06-10

No results posted yet for this study

Summary

RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of surgery with or without medroxyprogesterone may be an effective way to prevent the development of endometrial cancer in patients who have endometrial hyperplasia.

PURPOSE: Phase II trial to compare the effectiveness of surgery alone with that of medroxyprogesterone followed by surgery in preventing endometrial cancer in patients who have endometrial hyperplasia.

Conditions

Interventions

DRUG

medroxyprogesterone

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Gynecologic Oncology Group

    lead NETWORK

Principal Investigators

  • John P. Curtin, MD · Memorial Sloan Kettering Cancer Center

  • George L. Mutter, MD · Dana-Farber/Brigham and Women's Cancer Center

  • Francisco A. R. Garcia, MD, MPH · University of Arizona

  • Richard Zaino, MD · Milton S. Hershey Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1998-11-30
Primary Completion
2006-02-28

Countries

  • United States
  • Norway

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00003179 on ClinicalTrials.gov